Non-invasive tests can't go it alone in upper tract urothelial cancer surveillance

For patients with upper tract urothelial carcinoma (UTUC) managed with kidney-sparing endoscopic surgery, the appeal of replacing invasive ureteroscopy with CT scans and urine tests is understandable — but a new study says not so fast. Researchers from Paris and Milan analyzed 256 ureteroscopic procedures across 133 patients and found that while a combined CT urography and urinary cytology strategy could eliminate about 69% of ureteroscopies, it would also miss nearly 65% of recurrences.

The findings, published in BJU International, highlight a critical trade-off: non-invasive tests are simply not sensitive enough to safely stand alone. Of the missed recurrences, most were low-grade — but over 20% of those false-negative cases eventually required radical nephroureterectomy (kidney removal), underscoring the real clinical stakes.

By the Numbers

• 69.2% of ureteroscopies could be avoided with a combined CT/cytology trigger strategy
• 64.5% of recurrences would be missed using that same approach
• Urinary cytology alone: 97% specificity, but only 11% sensitivity
• CT urography alone: 27% sensitivity, 78% specificity
• 20.9% of false-negative cases later required radical nephroureterectomy

Why it matters: Ureteroscopy is invasive and resource-intensive, so reducing its frequency is an attractive goal. But this study makes clear that non-invasive tests aren't ready to take the wheel — they should be used to help stratify risk, not replace endoscopic surveillance entirely.